Genetics of Endocrine and Neuroendocrine Neoplasias–for health professionals (PDQ®)

SECTIONS

Changes to This Summary (02/18/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Multiple Endocrine Neoplasia Type 1 (MEN1)

Revised text to state that the age-related penetrance of MEN1 is 45% to 73% by age 30 years, 82% by age 50 years, and 96% by age 70 years (cited Goudet et al. as reference 6).

Added van Asselt et al. as reference 73.

Familial Paraganglioma Syndrome

Added Surveillance as a new subsection.

Added level of evidence 5 for surgical interventions in the treatment of familial paraganglioma syndrome.

Added level of evidence 5 for interventions in the treatment of Carney-Stratakis syndrome.

This summary is written and maintained by the PDQ Cancer Genetics Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Carney-Stratakis Syndrome

Next section >
About This PDQ Summary

Genetics of Endocrine and Neuroendocrine Neoplasias (PDQ)—Health Professional Version - National Cancer Institute